查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1596215

呼吸系统疾病检测市场：按产品和应用分类 - 2025-2030 年全球预测

Respiratory Disease Testing Market by Product (Blood Gas Test, Imaging Tests, Respiratory Measurement), End-Use (Clinical Laboratories, Hospitals, Physician Clinics) - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 199 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2023年，呼吸系统疾病检测市场价值为40.8亿美元，预计到2024年将达到42.6亿美元，复合年增长率为4.43%，到2030年预计将达到55.3亿美元。

呼吸系统疾病检测包括用于识别影响呼吸系统的感染疾病和慢性疾病的多种诊断方法。它包括肺活量测定、血液气体分析、诊断影像和分子诊断等各种测试，这些测试对于检测气喘、慢性阻塞性肺病、结核病和 COVID-19 等疾病至关重要。这些测试对于有效的疾病管理、早期诊断和个人化治疗至关重要，对医疗保健提供者和患者都有影响。由于污染、生活方式的改变和人口老化，全球呼吸系统疾病的盛行率不断增加，对准确、高效的检测解决方案的需求不断增长。关键的成长要素包括诊断技术的进步、医疗保健支出的增加以及对早期诊断益处的认识的提高。此外，COVID-19 大流行凸显了对快速、可靠的呼吸系统检测的需求，从而促进了市场的显着扩张和创新。开发用于即时分析的就地检验设备和整合人工智慧工具存在机会，可提供个人化和预测性见解。然而，市场扩张面临着监管障碍、先进诊断工具的高成本以及需要熟练的专业人员操作先进测试设备的挑战。由于医疗基础设施有限，新兴国家也面临限制。可以透过专注于便携式和侵入性较小的测试方法、整合数位健康解决方案以及对生物标记物进行研究以实现更准确的诊断来促进创新。在技​​术不断进步和对高效诊断解决方案的高需求的推动下，市场充满活力。相关人员必须投资于研究和开发，以利用这些进步，建立策略伙伴关係关係以提高市场渗透率，并确保遵守监管标准，以有效地利用新的机会。专注于降低成本和提高可及性可以显着加速市场进入并解决现有挑战。

主要市场统计
基准年[2023] 40.8亿美元
预测年份 [2024] 42.6亿美元
预测年份 [2030] 55.3亿美元
复合年增长率（%） 4.43%

市场动态：快速发展的呼吸道疾病检测市场的关键市场洞察

供需的动态交互作用正在改变呼吸系统疾病检测市场。了解这些不断变化的市场动态可以帮助企业做出明智的投资决策、策略决策并抓住新的商机。全面了解这些趋势可以帮助企业降低政治、地理、技术、社会和经济领域的风险，同时消费行为及其对製造成本的影响以及对采购趋势的影响。

  • 市场驱动因素
    • 呼吸道疾病增加
    • 采取不健康的生活方式和习惯，例如吸烟
    • 空气污染程度持续上升
    • 主要采用影像技术进行诊断
  • 市场限制因素
    • 替代系统和设备的可用性
  • 市场机会
    • 人们越来越偏好远端或居家照护测试设备
    • 研究开发测试方法和技术进步以获得有效、高效、快速的结果
  • 市场挑战
    • 缺乏保险报销政策

波特五力：驾驭呼吸道疾病检测市场的策略工具

波特的五力框架是理解市场竞争格局的重要工具。波特的五力框架为评估公司的竞争地位和探索策略机会提供了清晰的方法。该框架可帮助公司评估市场动态并确定新业务的盈利。这些见解使公司能够利用自己的优势，解决弱点并避免潜在的挑战，从而确保更强大的市场地位。

PESTLE分析：了解呼吸系统疾病检测市场的外部影响

外部宏观环境因素对呼吸系统疾病检测市场的表现动态起着至关重要的作用。对政治、经济、社会、技术、法律和环境因素的分析提供了应对这些影响所需的资讯。透过调查 PESTLE 因素，公司可以更了解潜在的风险和机会。这种分析可以帮助公司预测法规、消费者偏好和经济趋势的变化，并为他们做出积极主动的决策做好准备。

市场占有率分析 了解呼吸系统疾病检测市场的竞争状况

对呼吸系统疾病检测市场的详细市场占有率分析可以对供应商的表现进行全面评估。公司可以透过比较收益、客户群和成长率等关键指标来揭示其竞争地位。该分析揭示了市场集中、分散和整合的趋势，为供应商提供了製定策略决策所需的洞察力，使他们能够在日益激烈的竞争中占有一席之地。

FPNV 定位矩阵呼吸系统疾病检测市场供应商的绩效评估

FPNV定位矩阵是评估呼吸道疾病检测市场供应商的重要工具。此矩阵允许业务组织根据供应商的商务策略和产品满意度评估供应商，从而做出符合其目标的明智决策。这四个象限使您能够清晰、准确地划分供应商，并确定最能满足您的策略目标的合作伙伴和解决方案。

策略分析与建议，规划呼吸系统疾病检测市场的成功之路

对于旨在加强其在全球市场的影响力的公司来说，对呼吸系统疾病检测市场的策略分析至关重要。透过考虑关键资源、能力和绩效指标，公司可以识别成长机会并努力改进。这种方法使您能够克服竞争环境中的挑战，利用新的商机并取得长期成功。

本报告对市场进行了全面分析，涵盖关键重点领域：

1. 市场渗透率：详细检视当前市场环境、主要企业的广泛资料、评估其在市场中的影响力和整体影响力。

2. 市场开拓：辨识新兴市场的成长机会，评估现有领域的扩张潜力，并提供未来成长的策略蓝图。

3. 市场多元化：分析近期产品发布、开拓地区、关键产业进展、塑造市场的策略投资。

4. 竞争评估与情报：彻底分析竞争格局，检验市场占有率、业务策略、产品系列、认证、监理核准、专利趋势、主要企业的技术进步等。

5. 产品开发与创新：重点在于有望推动未来市场成长的最尖端科技、研发活动和产品创新。

我们也回答重要问题，帮助相关人员做出明智的决策：

1.目前的市场规模和未来的成长预测是多少？

2. 哪些产品、区隔市场和地区提供最佳投资机会？

3.塑造市场的主要技术趋势和监管影响是什么？

4.主要厂商的市场占有率和竞争地位如何？

5. 推动供应商市场进入和退出策略的收益来源和策略机会是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 呼吸道疾病发生率上升
      • 采取不健康的生活方式和习惯，例如吸烟
      • 空气污染水平持续上升
      • 大规模部署影像诊断技术
    • 抑制因素
      • 替代系统和设备的可用性
    • 机会
      • 远端或居家照护测试设备越来越受欢迎
      • 研究和开发测试方法和技术进步，以获得有效、高效和快速的结果。
    • 任务
      • 缺乏支持性报销政策
  • 市场区隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 经济
    • 社群
    • 技术的
    • 合法地
    • 环境

第六章呼吸系统疾病检测市场：副产品

  • 血气测试
  • 影像检查
  • 呼吸测量

第七章呼吸系统疾病检测市场：依最终用途分类

  • 临床实验室
  • 医院
  • 医生诊所

第八章 北美和南美呼吸疾病检测市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第九章亚太地区呼吸道疾病检测市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十章 欧洲、中东和非洲呼吸道疾病检测市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十一章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争情境分析
  • 战略分析和建议

公司名单

  • Abbott Laboratories
  • Becton, Dickinson and Company
  • Bio-Rad Laboratories, Inc.
  • Biomerieux
  • Cosmed
  • F. Hoffmann-La Roche Ltd.
  • Fujifilm Holdings
  • GE Healthcare
  • Hitachi Medical Corporation
  • Koninklijke Philips NV
  • Medtronic PLC
  • MGC Diagnostics Corporation by Caire Inc.
  • ResMed
  • SDI Diagnostics, Inc.
  • Seegene Inc.
  • Thermo Fisher Scientific
Product Code: MRR-035AB9C0DAAD

The Respiratory Disease Testing Market was valued at USD 4.08 billion in 2023, expected to reach USD 4.26 billion in 2024, and is projected to grow at a CAGR of 4.43%, to USD 5.53 billion by 2030.

Respiratory disease testing encompasses a broad range of diagnostic methods used to identify infections and chronic conditions affecting the respiratory system. The scope includes various tests like spirometry, blood gas analysis, imaging, and molecular diagnostics, imperative in detecting ailments such as asthma, COPD, tuberculosis, and COVID-19. These tests are essential for effective disease management, early diagnosis, and treatment personalization, impacting both healthcare providers and patients. With an increasing prevalence of respiratory diseases globally due to pollution, lifestyle changes, and aging populations, the demand for accurate and efficient testing solutions is escalating. Key growth influencers include technological advancements in diagnostics, rising healthcare expenditure, and increased awareness of early diagnosis benefits. Moreover, the COVID-19 pandemic has underscored the necessity for rapid and reliable respiratory testing, prompting substantial market expansion and innovation. Opportunities lie in the development of point-of-care testing devices and integrated AI tools for real-time analytics, providing personalized and predictive insights. However, market expansion is challenged by regulatory hurdles, the high cost of advanced diagnostic tools, and the need for skilled professionals to operate sophisticated testing equipment. Emerging economies also face constraints due to limited healthcare infrastructure. Innovation can thrive by focusing on portable and less invasive testing methods, integrating digital health solutions, and conducting research on biomarkers for more precise diagnostics. The market is dynamic, driven by the constant evolution of technology and the high demand for efficient diagnostic solutions. Stakeholders need to invest in R&D to leverage these advances, adopt strategic partnerships to enhance market penetration, and ensure compliance with regulatory standards to capitalize on emerging opportunities effectively. The emphasis on reducing costs and improving accessibility can significantly enhance market reach and address existing challenges.

KEY MARKET STATISTICS
Base Year [2023] USD 4.08 billion
Estimated Year [2024] USD 4.26 billion
Forecast Year [2030] USD 5.53 billion
CAGR (%) 4.43%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Respiratory Disease Testing Market

The Respiratory Disease Testing Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Rising incidence of respiratory diseases
    • Adoption of unhealthy lifestyle and habits such as tobacco smoking
    • Constantly rising air pollution levels
    • Major adoption of imaging technology for diagnostics
  • Market Restraints
    • Availability of alternatives systems and devices
  • Market Opportunities
    • Rising preferences for remote or home care testing devices
    • R&D and technology advancements in testing methods for effective, efficient, and faster results
  • Market Challenges
    • Lack of supportive reimbursement policies

Porter's Five Forces: A Strategic Tool for Navigating the Respiratory Disease Testing Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Respiratory Disease Testing Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Respiratory Disease Testing Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Respiratory Disease Testing Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Respiratory Disease Testing Market

A detailed market share analysis in the Respiratory Disease Testing Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Respiratory Disease Testing Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Respiratory Disease Testing Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Respiratory Disease Testing Market

A strategic analysis of the Respiratory Disease Testing Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Respiratory Disease Testing Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Becton, Dickinson and Company, Bio-Rad Laboratories, Inc., Biomerieux, Cosmed, F. Hoffmann-La Roche Ltd., Fujifilm Holdings, GE Healthcare, Hitachi Medical Corporation, Koninklijke Philips N.V, Medtronic PLC, MGC Diagnostics Corporation by Caire Inc., ResMed, SDI Diagnostics, Inc., Seegene Inc., and Thermo Fisher Scientific.

Market Segmentation & Coverage

This research report categorizes the Respiratory Disease Testing Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Product, market is studied across Blood Gas Test, Imaging Tests, and Respiratory Measurement.
  • Based on End-Use, market is studied across Clinical Laboratories, Hospitals, and Physician Clinics.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rising incidence of respiratory diseases
      • 5.1.1.2. Adoption of unhealthy lifestyle and habits such as tobacco smoking
      • 5.1.1.3. Constantly rising air pollution levels
      • 5.1.1.4. Major adoption of imaging technology for diagnostics
    • 5.1.2. Restraints
      • 5.1.2.1. Availability of alternatives systems and devices
    • 5.1.3. Opportunities
      • 5.1.3.1. Rising preferences for remote or home care testing devices
      • 5.1.3.2. R&D and technology advancements in testing methods for effective, efficient, and faster results
    • 5.1.4. Challenges
      • 5.1.4.1. Lack of supportive reimbursement policies
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Respiratory Disease Testing Market, by Product

  • 6.1. Introduction
  • 6.2. Blood Gas Test
  • 6.3. Imaging Tests
  • 6.4. Respiratory Measurement

7. Respiratory Disease Testing Market, by End-Use

  • 7.1. Introduction
  • 7.2. Clinical Laboratories
  • 7.3. Hospitals
  • 7.4. Physician Clinics

8. Americas Respiratory Disease Testing Market

  • 8.1. Introduction
  • 8.2. Argentina
  • 8.3. Brazil
  • 8.4. Canada
  • 8.5. Mexico
  • 8.6. United States

9. Asia-Pacific Respiratory Disease Testing Market

  • 9.1. Introduction
  • 9.2. Australia
  • 9.3. China
  • 9.4. India
  • 9.5. Indonesia
  • 9.6. Japan
  • 9.7. Malaysia
  • 9.8. Philippines
  • 9.9. Singapore
  • 9.10. South Korea
  • 9.11. Taiwan
  • 9.12. Thailand
  • 9.13. Vietnam

10. Europe, Middle East & Africa Respiratory Disease Testing Market

  • 10.1. Introduction
  • 10.2. Denmark
  • 10.3. Egypt
  • 10.4. Finland
  • 10.5. France
  • 10.6. Germany
  • 10.7. Israel
  • 10.8. Italy
  • 10.9. Netherlands
  • 10.10. Nigeria
  • 10.11. Norway
  • 10.12. Poland
  • 10.13. Qatar
  • 10.14. Russia
  • 10.15. Saudi Arabia
  • 10.16. South Africa
  • 10.17. Spain
  • 10.18. Sweden
  • 10.19. Switzerland
  • 10.20. Turkey
  • 10.21. United Arab Emirates
  • 10.22. United Kingdom

11. Competitive Landscape

  • 11.1. Market Share Analysis, 2023
  • 11.2. FPNV Positioning Matrix, 2023
  • 11.3. Competitive Scenario Analysis
  • 11.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Abbott Laboratories
  • 2. Becton, Dickinson and Company
  • 3. Bio-Rad Laboratories, Inc.
  • 4. Biomerieux
  • 5. Cosmed
  • 6. F. Hoffmann-La Roche Ltd.
  • 7. Fujifilm Holdings
  • 8. GE Healthcare
  • 9. Hitachi Medical Corporation
  • 10. Koninklijke Philips N.V
  • 11. Medtronic PLC
  • 12. MGC Diagnostics Corporation by Caire Inc.
  • 13. ResMed
  • 14. SDI Diagnostics, Inc.
  • 15. Seegene Inc.
  • 16. Thermo Fisher Scientific

LIST OF FIGURES

  • FIGURE 1. RESPIRATORY DISEASE TESTING MARKET RESEARCH PROCESS
  • FIGURE 2. RESPIRATORY DISEASE TESTING MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY PRODUCT, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY PRODUCT, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY END-USE, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY END-USE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. AMERICAS RESPIRATORY DISEASE TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 11. AMERICAS RESPIRATORY DISEASE TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. UNITED STATES RESPIRATORY DISEASE TESTING MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 13. UNITED STATES RESPIRATORY DISEASE TESTING MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. ASIA-PACIFIC RESPIRATORY DISEASE TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 15. ASIA-PACIFIC RESPIRATORY DISEASE TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. EUROPE, MIDDLE EAST & AFRICA RESPIRATORY DISEASE TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. EUROPE, MIDDLE EAST & AFRICA RESPIRATORY DISEASE TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. RESPIRATORY DISEASE TESTING MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 19. RESPIRATORY DISEASE TESTING MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. RESPIRATORY DISEASE TESTING MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. RESPIRATORY DISEASE TESTING MARKET DYNAMICS
  • TABLE 7. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY BLOOD GAS TEST, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY IMAGING TESTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY RESPIRATORY MEASUREMENT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY CLINICAL LABORATORIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY PHYSICIAN CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. AMERICAS RESPIRATORY DISEASE TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 16. AMERICAS RESPIRATORY DISEASE TESTING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 17. AMERICAS RESPIRATORY DISEASE TESTING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 18. ARGENTINA RESPIRATORY DISEASE TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 19. ARGENTINA RESPIRATORY DISEASE TESTING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 20. BRAZIL RESPIRATORY DISEASE TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 21. BRAZIL RESPIRATORY DISEASE TESTING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 22. CANADA RESPIRATORY DISEASE TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 23. CANADA RESPIRATORY DISEASE TESTING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 24. MEXICO RESPIRATORY DISEASE TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 25. MEXICO RESPIRATORY DISEASE TESTING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 26. UNITED STATES RESPIRATORY DISEASE TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 27. UNITED STATES RESPIRATORY DISEASE TESTING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 28. UNITED STATES RESPIRATORY DISEASE TESTING MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 29. ASIA-PACIFIC RESPIRATORY DISEASE TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 30. ASIA-PACIFIC RESPIRATORY DISEASE TESTING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 31. ASIA-PACIFIC RESPIRATORY DISEASE TESTING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 32. AUSTRALIA RESPIRATORY DISEASE TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 33. AUSTRALIA RESPIRATORY DISEASE TESTING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 34. CHINA RESPIRATORY DISEASE TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 35. CHINA RESPIRATORY DISEASE TESTING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 36. INDIA RESPIRATORY DISEASE TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 37. INDIA RESPIRATORY DISEASE TESTING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 38. INDONESIA RESPIRATORY DISEASE TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 39. INDONESIA RESPIRATORY DISEASE TESTING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 40. JAPAN RESPIRATORY DISEASE TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 41. JAPAN RESPIRATORY DISEASE TESTING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 42. MALAYSIA RESPIRATORY DISEASE TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 43. MALAYSIA RESPIRATORY DISEASE TESTING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 44. PHILIPPINES RESPIRATORY DISEASE TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 45. PHILIPPINES RESPIRATORY DISEASE TESTING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 46. SINGAPORE RESPIRATORY DISEASE TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 47. SINGAPORE RESPIRATORY DISEASE TESTING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 48. SOUTH KOREA RESPIRATORY DISEASE TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 49. SOUTH KOREA RESPIRATORY DISEASE TESTING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 50. TAIWAN RESPIRATORY DISEASE TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 51. TAIWAN RESPIRATORY DISEASE TESTING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 52. THAILAND RESPIRATORY DISEASE TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 53. THAILAND RESPIRATORY DISEASE TESTING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 54. VIETNAM RESPIRATORY DISEASE TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 55. VIETNAM RESPIRATORY DISEASE TESTING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 56. EUROPE, MIDDLE EAST & AFRICA RESPIRATORY DISEASE TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 57. EUROPE, MIDDLE EAST & AFRICA RESPIRATORY DISEASE TESTING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 58. EUROPE, MIDDLE EAST & AFRICA RESPIRATORY DISEASE TESTING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 59. DENMARK RESPIRATORY DISEASE TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 60. DENMARK RESPIRATORY DISEASE TESTING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 61. EGYPT RESPIRATORY DISEASE TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 62. EGYPT RESPIRATORY DISEASE TESTING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 63. FINLAND RESPIRATORY DISEASE TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 64. FINLAND RESPIRATORY DISEASE TESTING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 65. FRANCE RESPIRATORY DISEASE TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 66. FRANCE RESPIRATORY DISEASE TESTING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 67. GERMANY RESPIRATORY DISEASE TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 68. GERMANY RESPIRATORY DISEASE TESTING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 69. ISRAEL RESPIRATORY DISEASE TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 70. ISRAEL RESPIRATORY DISEASE TESTING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 71. ITALY RESPIRATORY DISEASE TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 72. ITALY RESPIRATORY DISEASE TESTING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 73. NETHERLANDS RESPIRATORY DISEASE TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 74. NETHERLANDS RESPIRATORY DISEASE TESTING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 75. NIGERIA RESPIRATORY DISEASE TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 76. NIGERIA RESPIRATORY DISEASE TESTING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 77. NORWAY RESPIRATORY DISEASE TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 78. NORWAY RESPIRATORY DISEASE TESTING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 79. POLAND RESPIRATORY DISEASE TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 80. POLAND RESPIRATORY DISEASE TESTING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 81. QATAR RESPIRATORY DISEASE TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 82. QATAR RESPIRATORY DISEASE TESTING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 83. RUSSIA RESPIRATORY DISEASE TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 84. RUSSIA RESPIRATORY DISEASE TESTING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 85. SAUDI ARABIA RESPIRATORY DISEASE TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 86. SAUDI ARABIA RESPIRATORY DISEASE TESTING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 87. SOUTH AFRICA RESPIRATORY DISEASE TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 88. SOUTH AFRICA RESPIRATORY DISEASE TESTING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 89. SPAIN RESPIRATORY DISEASE TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 90. SPAIN RESPIRATORY DISEASE TESTING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 91. SWEDEN RESPIRATORY DISEASE TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 92. SWEDEN RESPIRATORY DISEASE TESTING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 93. SWITZERLAND RESPIRATORY DISEASE TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 94. SWITZERLAND RESPIRATORY DISEASE TESTING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 95. TURKEY RESPIRATORY DISEASE TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 96. TURKEY RESPIRATORY DISEASE TESTING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 97. UNITED ARAB EMIRATES RESPIRATORY DISEASE TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 98. UNITED ARAB EMIRATES RESPIRATORY DISEASE TESTING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 99. UNITED KINGDOM RESPIRATORY DISEASE TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 100. UNITED KINGDOM RESPIRATORY DISEASE TESTING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 101. RESPIRATORY DISEASE TESTING MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 102. RESPIRATORY DISEASE TESTING MARKET, FPNV POSITIONING MATRIX, 2023